Royalty Pharma plc (MUN:RPD)
Germany
· Delayed Price · Currency is EUR | Market Cap | 16.75B |
| Revenue (ttm) | 2.03B |
| Net Income (ttm) | 656.62M |
| Shares Out | n/a |
| EPS (ttm) | 1.52 |
| PE Ratio | 25.52 |
| Forward PE | 6.96 |
| Dividend | 0.77 (2.31%) |
| Ex-Dividend Date | Feb 20, 2026 |
| Volume | 40 |
| Average Volume | 218 |
| Open | 33.17 |
| Previous Close | 34.06 |
| Day's Range | 33.17 - 33.50 |
| 52-Week Range | 30.41 - 34.06 |
| Beta | n/a |
| RSI | 62.40 |
| Earnings Date | Feb 11, 2026 |
About Royalty Pharma
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. [Read more]
Financial Performance
In 2025, Royalty Pharma's revenue was $2.38 billion, an increase of 5.06% compared to the previous year's $2.26 billion. Earnings were $770.95 million, a decrease of -10.25%.
Financial numbers in USD Financial StatementsNews
Royalty Pharma to Present at TD Cowen's 46th Annual Health Care Conference
NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference on March 3, 2...
Royalty Pharma: 2025 Financial Performance And Strategic Outlook
Royalty Pharma delivered robust FY25 results, with double-digit growth in Royalty Receipts and Portfolio Receipts, and disciplined capital deployment. RPRX expanded its portfolio through $2.6B in new ...
Royalty Pharma: Strong Execution And Visible Pipeline Support Our Buy View
Royalty Pharma delivered robust 2025 results, with Q4 receipts up 17% to $856 million and full-year portfolio receipts at $3.25 billion. The company deployed $2.6 billion into 9 new royalties and repu...
Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript
Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript
Royalty Pharma Reports Q4 and Full Year 2025 Results
Portfolio Rece ipts of $874 million in Q4 2025 and $3,254 million for FY 2025 Portfolio Receipts growth of 18% in Q4 2025 and 16% for FY 2025 Net cas h provided by operating activities of $827 million...
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 202...
Royalty Pharma plc (RPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Royalty Pharma plc (RPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Royalty Pharma plc (NASDAQ: RPRX) announced on Sunday a funding agreement of up to $500 million to accelerate the clinical development of Teva's an...
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments. Pablo Legorreta, Royalty Pharm...
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEV...
Royalty Pharma Announces Dividend Increase
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A or...
Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240 ...
Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an und...
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic roya...
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royal...
Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript
Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript
Royalty Pharma plc (RPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Royalty Pharma plc (RPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December:
Royalty Pharma: Guidance Raised Again, Platform Strength Intact -- Buy Reiterated
Royalty Pharma is reiterated as a Buy, supported by strong Q3 results, raised guidance, and disciplined capital deployment. The company trades at a notable discount to biopharma peers despite robust F...
Royalty Pharma plc (RPRX) Q3 2025 Earnings Call Transcript
Royalty Pharma plc ( RPRX) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants George Grofik - Senior VP and Head of Investor Relations & Communications Pablo Legorreta - Founder,...
Royalty Pharma Reports Third Quarter 2025 Results
Portfolio Receipts growth of 11% to $814 million; Royalty Receipts growth of 11% Net cash provided by operating activities of $703 million Raised full year 2025 guidance: Portfolio Receipts expected t...
Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences
NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Alnylam's AMVUTTRA from funds managed by B...
Royalty Pharma Declares Fourth Quarter 2025 Dividend
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2025 of $0.22 per Class A ordin...
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025 before the U.S...
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent di...